These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36813655)

  • 61. Targeting APOC3 in the familial chylomicronemia syndrome.
    Gaudet D; Brisson D; Tremblay K; Alexander VJ; Singleton W; Hughes SG; Geary RS; Baker BF; Graham MJ; Crooke RM; Witztum JL
    N Engl J Med; 2014 Dec; 371(23):2200-6. PubMed ID: 25470695
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Severe hypertriglyceridemia is primarily polygenic.
    Dron JS; Wang J; Cao H; McIntyre AD; Iacocca MA; Menard JR; Movsesyan I; Malloy MJ; Pullinger CR; Kane JP; Hegele RA
    J Clin Lipidol; 2019; 13(1):80-88. PubMed ID: 30466821
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Severe hypertriglyceridaemia and pancreatitis in a patient with lipoprotein lipase deficiency based on mutations in lipoprotein lipase (LPL) and apolipoprotein A5 (APOA5) genes.
    Koopal C; Bemelmans R; Marais AD; Visseren FL
    BMJ Case Rep; 2019 Apr; 12(4):. PubMed ID: 30948399
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Identification and Characterization of Two Novel Compounds: Heterozygous Variants of
    Wang S; Cheng Y; Shi Y; Zhao W; Gao L; Fang L; Jin X; Han X; Sun Q; Li G; Zhao J; Xu C
    Front Endocrinol (Lausanne); 2022; 13():874608. PubMed ID: 35923617
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Mutations in lipoprotein lipase that block binding to the endothelial cell transporter GPIHBP1.
    Voss CV; Davies BS; Tat S; Gin P; Fong LG; Pelletier C; Mottler CD; Bensadoun A; Beigneux AP; Young SG
    Proc Natl Acad Sci U S A; 2011 May; 108(19):7980-4. PubMed ID: 21518912
    [TBL] [Abstract][Full Text] [Related]  

  • 66. 10-Year Comparative Follow-up of Familial versus Multifactorial Chylomicronemia Syndromes.
    Belhassen M; Van Ganse E; Nolin M; Bérard M; Bada H; Bruckert E; Krempf M; Rebours V; Valero R; Moulin P
    J Clin Endocrinol Metab; 2021 Mar; 106(3):e1332-e1342. PubMed ID: 33221907
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Mutations in exon 3 of the lipoprotein lipase gene segregating in a family with hypertriglyceridemia, pancreatitis, and non-insulin-dependent diabetes.
    Wilson DE; Hata A; Kwong LK; Lingam A; Shuhua J; Ridinger DN; Yeager C; Kaltenborn KC; Iverius PH; Lalouel JM
    J Clin Invest; 1993 Jul; 92(1):203-11. PubMed ID: 8325986
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Familial chylomicronemia (type I hyperlipoproteinemia) due to a single missense mutation in the lipoprotein lipase gene.
    Ameis D; Kobayashi J; Davis RC; Ben-Zeev O; Malloy MJ; Kane JP; Lee G; Wong H; Havel RJ; Schotz MC
    J Clin Invest; 1991 Apr; 87(4):1165-70. PubMed ID: 2010533
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Therapeutic response to medium-chain triglycerides and omega-3 fatty acids in a patient with the familial chylomicronemia syndrome.
    Rouis M; Dugi KA; Previato L; Patterson AP; Brunzell JD; Brewer HB; Santamarina-Fojo S
    Arterioscler Thromb Vasc Biol; 1997 Jul; 17(7):1400-6. PubMed ID: 9261273
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Modifications of plasma lipoproteins after lipase activation in patients with chylomicronemia.
    Manzato E; Zambon S; Marin R; Baggio G; Crepaldi G
    J Lipid Res; 1986 Dec; 27(12):1248-58. PubMed ID: 3559389
    [TBL] [Abstract][Full Text] [Related]  

  • 71. GPIHBP1 autoantibody syndrome during interferon β1a treatment.
    Eguchi J; Miyashita K; Fukamachi I; Nakajima K; Murakami M; Kawahara Y; Yamashita T; Ohta Y; Abe K; Nakatsuka A; Mino M; Takase S; Okazaki H; Hegele RA; Ploug M; Hu X; Wada J; Young SG; Beigneux AP
    J Clin Lipidol; 2019; 13(1):62-69. PubMed ID: 30514621
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Familial chylomicronemia syndrome: The first case reported in Ecuador.
    Garay García KJ; Chong Menendez RJ; Nogueira JP; Piedra Andrade JS
    Clin Investig Arterioscler; 2022; 34(6):326-329. PubMed ID: 36184299
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Lipoprotein Lipase Deficiency Arising in Type V Dyslipidemia.
    Tanaka S; Ueno T; Tsunemi A; Nakamura Y; Kobayashi H; Hatanaka Y; Haketa A; Fukuda N; Soma M; Abe M
    Intern Med; 2019 Jan; 58(2):251-257. PubMed ID: 30210108
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Unfolding of monomeric lipoprotein lipase by ANGPTL4: Insight into the regulation of plasma triglyceride metabolism.
    Kristensen KK; Leth-Espensen KZ; Mertens HDT; Birrane G; Meiyappan M; Olivecrona G; Jørgensen TJD; Young SG; Ploug M
    Proc Natl Acad Sci U S A; 2020 Feb; 117(8):4337-4346. PubMed ID: 32034094
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Volanesorsen for treatment of familial chylomicronemia syndrome.
    Lazarte J; Hegele RA
    Expert Rev Cardiovasc Ther; 2021 Aug; 19(8):685-693. PubMed ID: 34261380
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Post-heparin LPL activity measurement using VLDL as a substrate: a new robust method for routine assessment of plasma triglyceride lipolysis defects.
    Di Filippo M; Marçais C; Charrière S; Marmontel O; Broyer M; Delay M; Merlin M; Nollace A; Valéro R; Lagarde M; Pruneta-Deloche V; Moulin P; Sassolas A
    PLoS One; 2014; 9(6):e99721. PubMed ID: 24886863
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A case of hyperchylomicronemia associated with GPIHBP1 autoantibodies and fluctuating thyroid autoimmune disease.
    Nozue T; Tada H; Murakami M; Michishita I
    J Clin Lipidol; 2023; 17(1):68-72. PubMed ID: 36402671
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Severe hypertriglyceridemia secondary to splice-site and missense variants in LMF1 in three patients from Ecuador.
    Garay-García K; Gaete PV; Mendivil CO
    J Clin Lipidol; 2022; 16(3):277-280. PubMed ID: 35246399
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Challenges in familial chylomicronemia syndrome diagnosis and management across Latin American countries: An expert panel discussion.
    Santos RD; Lorenzatti A; Corral P; Nogueira JP; Cafferata AM; Aimone D; Lourenço CM; Izar MC; Lima JG; Lottenberg AM; Alonso R; Garay K; Morales AR; Vargas-Uricoechea H; Peña CAC; Roman-González A
    J Clin Lipidol; 2021; 15(5):620-624. PubMed ID: 34920815
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Intermittent chylomicronemia caused by intermittent GPIHBP1 autoantibodies.
    Ashraf AP; Miyashita K; Nakajima K; Murakami M; Hegele RA; Ploug M; Fong LG; Young SG; Beigneux AP
    J Clin Lipidol; 2020; 14(2):197-200. PubMed ID: 32107180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.